QT Imaging Leverages NVIDIA L40 GPU Acceleration to Power its Next-Gen Breast Imaging Reconstruction Software

– New software release delivers substantial image processing time improvements –

– Faster image availability enables radiologists to review and interpret QTI breast scans more quickly, supporting earlier clinical decision-making –

– Image fidelity and diagnostic accuracy improvement, in addition to the significant processing speed gains –

QT Imaging Holdings, Inc. (OTCQB:QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce its latest image reconstruction software update release, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency. The software update was developed leveraging NVIDIA’s L40 GPU, powered by the Ada Lovelace architecture.

The U.S. FDA-cleared QTI Breast Acoustic CT™ scanner is the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation. Despite the processing speed gains achieved via the version 4.4.0 software update, QTscan breast image fidelity and diagnostic accuracy are uncompromised, and image quality remains best-in-class, with a resolution similar to magnetic resonance imaging (MRI).

Designed to meet the needs of busy breast imaging centers, the software update ensures minimal downtime and seamless integration into existing workflows. Accordingly, it enhances scalability for institutions expanding their QTI breast screening programs, ensuring consistent performance across increasing patient volumes.

“This latest software release reflects direct input from radiologists and clinical partners, underscoring our commitment to continuous innovation based on real-world use,” said QTI’s CEO, Dr. Raluca Dinu. “Faster image availability enables radiologists to review and interpret QTI scans more quickly, supporting earlier clinical decision-making. And accelerated processing reduces wait times for results, contributing to a smoother and more reassuring patient journey.”

The QTI team continues to innovate by leveraging proprietary machine learning algorithms not only to accelerate image processing via the version 4.4.0 software update, but also to actively reduce scanning time — a key focus area in ongoing development. Version 4.4.0 is optimized for systems utilizing NVIDIA’s L40 GPUs and remains fully backward-compatible with earlier QTI system hardware, ensuring broad accessibility through scalable, software-driven architecture.

About QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, including the software update, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250625121052/en/